Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study
European Journal of Clinical Microbiology & Infectious Diseases · 2024
DOI: 10.1007/s10096-024-04833-8 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2024. Verfasst von Alessandra Oliva und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, 00185, Italy. alessandra.oliva@uniroma1…. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections, Anti-Bacterial Agents, Carbapenems. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma La Sapienza.
Abstract (Originalsprache)
Background
We assessed the clinical effectiveness of cefiderocol (CFDC) in comparison with colistin (COL) for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections (BSI). Materials/methods Retrospective cohort study including adults with CRAB-BSI. Outcomes were mortality, clinical cure and adverse events during therapy. The average treatment effect of CFDC compared to COL was weighted with the inverse-probability treatment weight (IPTW).
Results
Overall, 104 patients were included (50 CFDC, 54 COL), median age 66.5 years, median Charlson Comorbidity Index 5, septic shock in 33.6% of patients. Primary BSI accounted for 43.3% of cases, followed by ventilator-associated pneumonia (VAP) (26%), catheter-related BSI (20.2%) and hospital-acquired pneumonia (HAP) (9.6%). Although not significantly, mortality at all time points was lower for CFDC than COL, while clinical cure was higher in CFDC than COL (66% vs. 44.4%, p = 0.027). Adverse events were more frequent in COL than CFDC-group (38.8% vs. 10%, p < 0.0001), primarily attributed to acute kidney injury (AKI) in the COL group. Patients with bacteremic HAP/VAP treated with CFDC had a significant lower 30-d mortality and higher clinical cure than COL ( p = 0.008 and p = 0.0008, respectively). Increment of CCI ( p = 0.005), ICU ( p = 0.025), SARS-CoV2 ( p = 0.006) and ECMO ( p < 0.0001) were independently associated with 30-d mortality, while receiving CFDC was not associated with survival.
Conclusions
CFDC could represent an effective and safe treatment option for CRAB BSI, especially in patients with bacteremic HAP/VAP and frail patients where the risk of acute renal failure during therapy should be avoided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, 00185, Italy. alessandra.oliva@uniroma1.it.
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, 00185, Italy.
- Microbiology and Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
- Department of General and Specialistic Surgery, Sapienza University of Rome, Rome, Italy.
Förderung
- Università degli Studi di Roma La Sapienza
Zitieren
APA
Oliva, A., Liguori, L., Covino, S., Petrucci, F., Cogliati-Dezza, F., Curtolo, A., Savelloni, G., Comi, M., Sacco, F., Ceccarelli, G., Viscido, A., Alessandri, F., Raponi, G., Pugliese, F., Mastroianni, C. M., & Venditti, M. (2024). Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-024-04833-8
Vancouver
Oliva A, Liguori L, Covino S, Petrucci F, Cogliati-Dezza F, Curtolo A, et al. Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study. European Journal of Clinical Microbiology & Infectious Diseases. 2024. doi:10.1007/s10096-024-04833-8
BibTeX
@article{Oliva2024,
author = {Oliva, Alessandra and Liguori, L and Covino, S and Petrucci, F and Cogliati-Dezza, F and Curtolo, A and Savelloni, G and Comi, M and Sacco, F and Ceccarelli, G and Viscido, A and Alessandri, F and Raponi, G and Pugliese, F and Mastroianni, C M and Venditti, M},
title = {Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study},
journal = {European Journal of Clinical Microbiology & Infectious Diseases},
year = {2024},
doi = {10.1007/s10096-024-04833-8}
}
EUVIMED